Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

ClinicalTrials.gov ID: NCT07074977

Public ClinicalTrials.gov record NCT07074977. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Exploratory Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics (PK/PD) of Nemolizumab in Adult Participants With Chronic Pruritus of Unknown Origin (CPUO)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.

Study identification

NCT ID
NCT07074977
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Galderma R&D
Industry
Enrollment
50 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 19, 2025
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026
Last update posted
Jul 26, 2026

2025 – 2027

United States locations

U.S. sites
25
U.S. states
18
U.S. cities
25
Facility City State ZIP Site status
Galderma Investigational Site (site# 8893) Birmingham Alabama 35244
Galderma Investigational Site (#8768) Tucson Arizona 85718
Galderma Investigational Site (site# 8636) Fountain Valley California 92708
Galderma Investigational Site (site# 8130) Los Angeles California 90045
Galderma Investigational Site (#9975) Sacramento California 95815
Galderma Investigational Site (site# 8021) San Diego California 92123
Galderma Investigational Site (site# 7075) San Francisco California 94115
Galderma Investigational Site (site# 8608) Santa Monica California 90404
Galderma Investigational Site (#8295) Miami Florida 33136
Galderma Investigational Site (site# 7054) Tampa Florida 33609
Galderma Investigational Site (site# 8142) Indianapolis Indiana 46250
Galderma Investigational Site (#7129) Bowling Green Kentucky 42104
Galderma Investigational (Site# 7048) Baltimore Maryland 21201
Galderma Investigational Site (site# 8743) Ann Arbor Michigan 48109
Galderma Investigational Site (site# 8521) Saint Joseph Missouri 64506
Galderma Investigational Site (site# 8108) Las Vegas Nevada 89145
Galderma Investigational Site (site# 7110) New City New York 10956
Galderma Investigational Site (#7130) The Bronx New York 10455
Galderma Investigational Site (site# 7111) Fargo North Dakota 58103
Galderma Investigational Site (#8212) Portand Oregon 97210
Galderma Investigational Site (#8255) Philadelphia Pennsylvania 19103
Galderma Investigational (Site # 7131) Spartanburg South Carolina 29307
Galderma Investigational Site (site# 8003) Webster Texas 77598
Galderma Investigational Site (site# 8862) Fairfax Virginia 22031
Galderma Investigational Site (site# 8725) Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07074977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 26, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07074977 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →